Source-grounded facts extracted from ABVC BIOPHARMA, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ABVC BIOPHARMA, INC. reported that prior financial statements should not be relied upon.
“atters disclosed in this Item 4.02 with its independent registered public accounting firm, Simon & Edward, LLP. Due to the above, the Company determined that it has a material weakness in its internal controls over financial reporting and shall include such determination in its Annual Report on Form”
Uttam Patil changed role as interim Chief Financial Officer at ABVC BIOPHARMA, INC..
“While the Company is looking for a full-time Chief Financial Officer to fill the vacancy created by Leeds Chow’s resignation, the Company’s CEO, Uttam Patil will serve as the interim Chief Financial Officer of the Company.”
Leeds Chow resigned as Chief Financial Officer at ABVC BIOPHARMA, INC..
“On March 5, 2025, Mr. Leeds Chow, the Chief Financial Officer (“CFO”) of ABVC BioPharma, Inc. (the “Company”) notified the Company of his resignation as CFO.”
ABVC BIOPHARMA, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“January 9, 2025, ABVC BioPharma, Inc. (the "Company") received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share, as”
Uttam Patil was appointed as interim Chief Financial Officer at ABVC BIOPHARMA, INC..
“The Company’s CEO, Uttam Patil, will assume the duties of interim Chief Financial Officer until the parties settle the disagreement and Leeds resumes his position as CFO.”
Leeds Chow departed as Chief Financial Officer at ABVC BIOPHARMA, INC..
“due to disagreements regarding salaries due and payable, Mr. Chow has informed the Company that he is suspending his work as CFO.”
ABVC BIOPHARMA, INC. terminated Land Transfer Agreement with Shuling Jiang valued at Not disclosed (effective 2024-05-16).
“On May 16, 2024, the Company’s board of directors determined that it was in the best interest of the Company and its shareholders to terminate the Agreement and not proceed with the transfer of land ownership at this time”
ABVC BIOPHARMA, INC. entered into Land Transfer Agreement with Shuling Jiang valued at Not disclosed (effective 2024-02-08).
“On February 8, 2024, ABVC BioPharma, Inc. (the “ Company ”) filed the initial Current Report on Form 8-K to disclose that it entered into a definitive agreement with Shuling Jiang (“ Jiang ”), pursuant to which Jiang was going to transfer the ownership of certain land she owns located at Taoyuan City, Taiwan (the “ Land ”) to the Company (the “ Agreement ”).”
ABVC BIOPHARMA, INC. entered into Oncox Agreement with OncoX BioPharma, Inc. valued at Total of $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share) and an additional milestone p (effective 2024-05-14).
“On May 14, 2024, the Company entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (“ Oncox ”), pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC’s BLEX 404 single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Tripple Negative Breast Cancer (the “ Licensed Products ”), within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the “ Oncox Agreement ”).”
ABVC BIOPHARMA, INC. entered into Oncox Agreement with OncoX BioPharma, Inc. valued at $6,250,000 (effective 2024-05-08).
“ompany entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (“ Oncox ”),”
ABVC BIOPHARMA, INC. shareholders approved To approve an increase in the company’s Amended and Restated 2016 Equity Incentive Plan up to a maximum of 15% of current issued and outstanding shares at the 2024-04-16 meeting.
“For Against Abstain 4,483,481 96,204 6,415”
ABVC BIOPHARMA, INC. shareholders approved To authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock underlying convertible notes and warrants issued by us pursuant to the terms of that certain Securities Purchase Agreement dated February 23, 2023, and certain Securities Purchase Agr at the 2024-04-16 meeting.
“For Against Abstain 4,497,446 77,101 11,553”
ABVC BIOPHARMA, INC. shareholders approved To ratify the appointment of WWC P.C. CPA as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-04-16 meeting.
“For Against Abstain 5,449,292 123,503 163,220”
ABVC BIOPHARMA, INC. shareholders approved To re-elect 11 directors to the Company’s board of directors at the 2024-04-16 meeting.
“Eugene Jiang 4,542,439 0 43,661”
ABVC BIOPHARMA, INC. entered into Oncox Agreement with OncoX BioPharma, Inc. valued at $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share) (effective 2024-04-16).
“On April 16, 2024, the Company entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (" Oncox "), pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC's single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer (the “ Licensed Products ”), within North America for 20 years (the “ Oncox Agreement ”).”
ABVC BIOPHARMA, INC.: Amended Section 2.8 of Bylaws to reduce shareholder meeting quorum from a majority to 33-1/3% of votes entitled to be cast (effective 2024-03-14).
“the Board approved to amend Section 2.8 of the Company’s Bylaws to revise the number of shares needed to establish a quorum at shareholder meetings (the “Amendment”). The Amendment changes the quorum requirement from a majority to 33-1/3% of the votes entitled to be cast on a matter. The Amendment is effective as of March 14, 2024.”
ABVC BIOPHARMA, INC. reported financial results for the fiscal year ended December 31, 2023.
“ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results.”
ABVC BIOPHARMA, INC. amended Amendment with Lind Global Fund II, LP valued at conversion price shall have a floor price of $1.00 (effective 2024-01-17).
“the parties entered into an amendment to the Note, pursuant to which the conversion price shall have a floor price of $1.00 (the “Amendment”).”
ABVC BIOPHARMA, INC. amended Amendment to Note with Lind Global Fund II, LP valued at Conversion price floor of $1.00; cash payment to Lind if floor price triggered (effective 2023-11-20).
“We are filing this amendment to disclose that due to Nasdaq requirements, the parties entered into an amendment to the Note, pursuant to which the conversion price shall have a floor price of $1.00 (the “Amendment”). Additionally, the Amendment requires the Company to make a cash payment to Lind if in connection with a conversion, the conversion price is deemed to be the floor price.”
ABVC BIOPHARMA, INC. entered into Agreement with Shuling Jiang valued at approximately $2,962,232 (effective 2024-02-06).
“On February 06, 2024, ABVC BioPharma, Inc. (the “ Company ”) entered into a definitive agreement with Shuling Jiang (“ Jiang ”), pursuant to which Jiang shall transfer the ownership of certain land she owns located at Taoyuan City, Taiwan (the “ Land ”) to the Company (the “ Agreement ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.